he maker of the popular painkiller Nurofen was ordered on Monday to remove some of its brands from store shelves in Australia.
The Federal Court ruled that UK-based drug giant Reckitt Benckiser made misleading claims about the pills’ effectiveness.
The court said Nurofen’s back pain, period pain, migraine pain, and tension headache brands were identical to standard Nurofen – despite being nearly double the price.
Ruling on complaints made by the fair trading regulator, the Australian Competition and Consumer Commission, the court found all the products contained the same amount of the active ingredient: 342 milligrams of ibuprofen lysine.
The drugs were “no more effective at treating the type of pain described on its packaging than any of the other Nurofen Specific Pain products”, the court ruled, according to an ACCC statement.
Full content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand